Two ongoing phase 2, multicenter, randomized, placebo-controlled, dose-escalation trials (NCT05246033, NCT04085523) are investigating the safety, efficacy, and pharmacokinetics of multiple subcutaneous doses of TransCon CNP administered once weekly in prepubertal children (aged 2-10 years) with achondroplasia. This evidence concerns the gene CNP and achondroplasia.